搜索结果


   PDE10A

靶点ID:TCMBANKGE008723


靶点别名:ADSD2; HSPDE10A; IOLOD; LINC00473; PDE10A19


靶点描述:phosphodiesterase 10A


染色体:6


染色体位置:6q27


靶点类型:protein-coding


HERB_ID:HBTAR006052


HGNC_Link:8772


OMIM_Link:610652


Ensembl_Link:ENSG00000112541


   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族

   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN001763 (E)-2,3-bis(2-keto-7-methoxy-chromen-8-yl)acrolein (E)-2,3-bis(7-methoxy-2-oxochromen-8-yl)prop-2-enal; (E)-2,3-bis(7-methoxy-2-oxo-8-chromenyl)prop-2-enal; (E)-2,3-bis(7-methoxy-2-oxo-chromen-8-yl)prop-2-enal C23H16O7 404.37
TCMBANKIN006653 dehydrocorydaline CHEBI:81342; BG01347441; LS-43470; FT-0624497; 10605-03-5 (chloride); 8095AH; ZINC597214; Dibenzo[a,g]quinolizinium,5,6-dihydro-2,3,9,10-tetramethoxy-13-methyl-; BERBINIUM, 7,8,13,13a-TETRADEHYDRO-2,3,9,10-TETRAMETHOXY-13-METHYL-; MolPort-020-006-016; 9323AF; DHC; 30045-16-0; Dibenzo(a,g)quinolizinium, 5,6-dihydro-2,3,9,10-tetramethoxy-13-methyl- (9CI); BRN 1556798; HY-N0674; AKOS030526131; Dibenzo(a,g)quinolizinium, 5,6-dihydro-2,3,9,10-tetramethoxy-13-methyl-; 7,8,13,13a-Tetradehydro-2,3,9,10-tetramethoxy-13-methylberbinium; CHEMBL1917176; 2,3,9,10-tetramethoxy-13-methyl-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium; AK546656; C17790; Q-100383; AC1L1SAF; SCHEMBL14513602; N2090; Dehydrocorydaline; 5-21-06-00206 (Beilstein Handbook Reference); C22H24NO4; 3,4,10,11-TETRAMETHOXY-13-METHYL-7,8-DIHYDRO-6??-AZATETRAPHEN-6-YLIUM; Dehydrocorydalin C22H24NO4+ 366.4 g/mol CC1=C2C=CC(=C(C2=C[N+]3=C1C4=CC(=C(C=C4CC3)OC)OC)OC)OC
TCMBANKIN020949 papaverine Cepaverin; AOB5339; 58-74-2; MFCD00012745; ZINC00056555; NCI60_003183; Drapavel; DSSTox_RID_77939; NCI-C56359; Myobid; BB_NC-0726; H754; Isoquinoline, 6,7-dimethoxy-1-veratryl-, hydrochloride; Papaverine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material; Dynovas; Artegodan; Papavarine chlorhydrate; DTXSID9025825; NCGC00094258-03; Isoquinoline,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-, hydrochloride; 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; Alapav; Papacon; AIDS000185; NSC35443 (HCL); SMR000058283; KBioGR_000914; Spasmo-Nit; Papavarine hydrochloride; HMS1569F08; 1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-isoquinoline; DSSTox_CID_5825; Papaverine hydrochloride (JP17/USP); Pameion; NCGC00094258-06; BSPBio_002153; Chlorhydrate de papaverine [French]; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-, hydrochloride (1:1); SBB080541; AIDS-000185; Oprea1_387689; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; I01-13837; Optenyl; CTK8G2272; Papaverine Hcl; WLN: T66 CNJ B1R CO1 DO1& HO1 IO1; Dispamil; Lopac0_000957; Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-; Isoquinoline,7-dimethoxy-1-veratryl-, hydrochloride; MLS000028497; KBio2_005607; Lapav; Ro-Papav; Papanerin-HCl [German]; Cardiospan; Tox21_110226_1; TNP00305; Pavnell; HMS1920F06; LP00957; Pavagrant; SR-01000003098-2; SDCCGMLS-0003037.P003; AC1L1LRO; 6,7,3',4'-Tetramethoxy-1-benzylisoquinoline hydrochloride; 6,7-Dimethoxy-1-veratrylisoquinoline; Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); TR-031684; Pavacot; Papaverine hydrochloride, United States Pharmacopeia (USP) Reference Standard; Paveron; Spectrum4_000467; Spectrum_000071; LS-267; SR-01000003098-11; Forpavin; Durapav; Cardoverina; Prestwick2_000583; Papaverine hydrochloride, powder; CCRIS 3804; 5-21-06-00182 (Beilstein Handbook Reference); Paverolan; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline hydrochloride; 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline; FT-0631269; ACon1_002094; NCGC00094258-04; EINECS 200-397-2; Papaverine; AC1Q3DLI; CHEMBL98123; Pavadel; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline hydrochloride; 58-74-2 (Parent); InChI=1/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H; REGID_for_CID_6084; BBC/116; Dipav; NCGC00094258-01; P0016; SPBio_002645; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; 6,7-Dimethoxy-1-veratrylisoquinoline hydrochloride; NCGC00261642-01; PubChem6305; Cerebid; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; Oprea1_810508; Vasal; Papanerin; P 3510; 23473EC6BQ; Pharmakon1600-01500459; C06533; Lopac-P-3510; Vaso-Pav; SCHEMBL121268; DivK1c_000321; Papaverina [Italian]; NSC136630; NSC 136630; KBio2_000471; Spectrum3_000537; MLS002222208; component of Copavin; 58-74-2 (FREE BASE ); Therapav; BG00717685; Prestwick1_000583; Pavacen; Copavin; AK-67336; Dilaves; PAP H; 4-[(6,7-dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene, chloride; UNII-23473EC6BQ; NCGC00015810-01; Papaversan; Tox21_500957; DSSTox_GSID_25825; Papaverine chlorohydrate; Papaverine hydrochloride [USAN:JAN]; EINECS 200-502-1; EU-0100957; Robaxapap; NCGC00094258-02; Papaverine hydrochloride [USP:JAN]; Papaverine, hydrochloride; Papaverine (hydrochloride); PAPAVERINE HYDROCHLORIDE; Prestwick0_000583; MEGxp0_001880; Delapav; D02218; Pavacap; BPBio1_000470; Ceraspan; AS-13262; NCGC00015810-03; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-, hydrochloride; Papanerin-hcl; NCGC00015810-12; KB-146860; RS 47; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline;hydrochloride; CAS-61-25-6; UOTMYNBWXDUBNX-UHFFFAOYSA-N; Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-, hydrochloride (1:1); Papaverin; ACon1_000238; KBio2_003039; Prestwick3_000583; Pavabid (TN); Papaverine monohydrochloride; WLN: T66 CNJ B1R CO1 DO1& HO1 IO1 &GH; NSC757256; Pavatest; Papaverinium chloride; SR-01000003098; ST077145; ST023301; Pavakey; NSC-35443; BRN 0312930; Isoquinoline, 6,7-dimethoxy-1-veratryl- (8CI); SR-01000003098-9; 61-25-6 (HCL); SPBio_001015; NSC35443; MLS001148655; BSPBio_000426; IDI1_000321; Spectrum2_000978; Pavased; SPECTRUM1500459; Papanerine; NSC-757256; NCGC00094258-05; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)-isoquinoline hydrochloride; KBioSS_000471; HY-18077A; Papaverine hydrochloride, European Pharmacopoeia (EP) Reference Standard; BG01663857; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinolinehydrochloride; S-M-R; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; NINDS_000321; Papalease; Papaverine hydrochlorid; KBio3_001653; Pap-Kaps-150; MolPort-000-847-203; NCGC00015810-02; Isoquinoline, 6,7-dimethoxy-1-veratryl-; API0003748; CCG-40065; CS-5015; BAS 00674058; ARONIS23834; AKOS005111070; 61-25-6; NSC 35443; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; C20H22ClNO4; 1-(3,7-dimethoxyisoquinoline hydrochloride; Isoquinoline, 6,7-dimethoxy-1-veratryl-, hydrochloride (8CI); Tox21_110226; 6,3',4'-Tetramethoxy-1-benzylisoquinoline hydrochloride; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-isoquinoline; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; Spectrum5_001188; Opera_ID_1617; Prestwick_376; SR-01000003098-4; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-; KBio1_000321 C20H21NO4 339.39 COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC
TCMBANKIN023120 4-(3,4-dimethoxyphenyl)-6-hydroxy-5-methoxynaphthalene-2-carbaldehyde 4-(3,4-dimethoxyphenyl)-6-hydroxy-5-methoxy-naphthalene-2-carbaldehyde; 4-(3,4-dimethoxyphenyl)-6-hydroxy-5-methoxy-2-naphthalenecarboxaldehyde 338.38
TCMBANKIN024944 isoyatein C22H24O7 400.42 COC1=CC(=CC(=C1OC)OC)CC2COC(=O)C2CC3=CC4=C(C=C3)OCO4
TCMBANKIN029879 Cavidine 32728-75-9; 9-Dimethoxy-6-methyl-6,6a,11,14-tetrahydro-8,12H-benzo(a)-1,3-benzodioxolo(4,5-g)quinolizine C21H23NO4 353.41 CC1C2C3=CC(=C(C=C3CCN2CC4=C1C=CC5=C4OCO5)OC)OC
TCMBANKIN031363 dimethyl sulfoxide C2H6OS 78.14 g/mol CS(=O)C
TCMBANKIN034667 (-)-Tabernemontanine C21H26N2O3 354.44 CCC1CN(C2CC3=C(C(=O)CC1C2C(=O)OC)NC4=CC=CC=C34)C
TCMBANKIN034837 corycavine 7,16-Dimethyl-6,8,9,16-tetrahydrobis(1,3)benzodioxolo(4,5-c:5',6'-g)azecin-15(7H)-one; BG01348418; NSC123402; BRD-A25851298-001-01-3; NSC 123402; C-54667; WOLWLEQYUFDNTA-UHFFFAOYSA-N; 521-87-9; NCI60_000225; AC1Q6P90; Ambap521-85-7; 7,16-Dimethyl-6,8,9,16-tetrahydrobis[1,3]benzodioxolo[4,5-c:5',6'-g]azecin-15(7H)-one; Bis[1,3]benzodioxolo[4,5-c:5',6'-g]azecin-13(5H)-one, 4,6,7,14-tetrahydro-5,14-dimethyl-, (R)-; Corycavamine, (+/-)-; 2,15-DIMETHYL-7,9,19,21-TETRAOXA-15-AZAPENTACYCLO[15.7.0.0?,(1)(2).0?,(1)?.0(1)?,(2)(2)]TETRACOSA-1(24),4,6(10),11,17,22-HEXAEN-3-ONE; AKOS000277068; ACon1_002262; ACM521857; NSC-123402; CORYCAVINE; Dibenzo[c,g]azecin-13-one, perhydro-6,14-dimethyl-3,4:10,11-bis(methylenedioxy)-; AC1L5J6U; 7,16-Dimethyl-6,8,9,16-tetrahydrodi[1,3]benzodioxolo[4,5-c:5,6-g]azecin-15(7H)-one # C21H21NO5 367.4 CC1C2=C(CN(CCC3=CC4=C(C=C3C1=O)OCO4)C)C5=C(C=C2)OCO5
TCMBANKIN038711 Columbamine BDBM50226664; Dibenzo[a,g]quinolizinium, 5,6-dihydro-2-hydroxy-3,9,10-trimethoxy-; SCHEMBL422073; HY-N0926; AKOS030526792; CS-4254; STOCK1N-48595; 5,6-dihydro-2-hydroxy-3,9,10-trimethoxydibenzo[a,g]quinolizinium; FT-0723334; 3621-36-1; 7T4808FEJW; 2-hydroxy-3,9,10-trimethoxy-5,6-dihydroisoquino[3,2-a]isoquinolinium; AC1Q7BDJ; CHEBI:15920; KS-00000TTK; DTXSID80189766; 3,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium-2-ol; CTK4H6087; AC1L2HU1; Dibenzo(a,g)quinolizinium, 5,6-dihydro-2-hydroxy-3,9,10-trimethoxy-; C01795; 5,6-Dihydro-2-hydroxy-3,9,10-trimethoxydibenzo[a,g]quinolizinium iodide; columbamine ; MCULE-1960820824; 3,9,10-trimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-2-ol; UNII-7T4808FEJW; Dehydroisocorypalmine; 7,8,13,13a-tetradehydro-2-hydroxy-3,9,10-trimethoxyberbinium; MolPort-002-523-367; YYFOFDHQVIODOQ-UHFFFAOYSA-O; Dibenzo[a,g]quinolizinium,5,6-dihydro-2-hydroxy-3,9,10-trimethoxy-; LS-182873; ZINC338120; AK547771; Columbamine; 9161AF; CHEMBL400345 C20H20NO3 323 c1(OC([H])([H])[H])c([H])c(C([H])([H])C([H])([H])N(C([H])=C(C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C2[H])C2=C3[H])=C34)c4c([H])c1[H]
TCMBANKIN040747 Epiberberine SMR000232286; AK199153; BDBM50986; 16,17-DIMETHOXY-5,7-DIOXA-1??-AZAPENTACYCLO[11.8.0.0_,__.0?,?.0_?,_?]HENICOSA-1(13),2,4(8),9,11,14(19),15,17-OCTAEN-1-YLIUM; SC-81909; ZINC6017816; CTK5C8375; FT-0688286; Epiberberine; DTXSID90218854; 16,17-DIMETHOXY-5,7-DIOXA-1??-AZAPENTACYCLO[11.8.0.0(3),(1)(1).0?,?.0(1)?,(1)?]HENICOSA-1(13),2,4(8),9,11,14(19),15,17-OCTAEN-1-YLIUM; MolPort-039-052-346; HMS3358O04; AKOS025149077; GNF-Pf-2355; 8,9-Dimethoxy-11,12-dihydro-[1,3]dioxolo[4,5-h]isoquinolino[2,1-b]isoquinolin-13-ium; epiberberine ; NCGC00247623-01; CHEMBL1197637; N2453; HMS2229E04; 6873/9/2; MLS000563434; Benz(a)-1,3-benzodioxolo(4,5-g)quinolizinium, 11,12-dihydro-8,9-dimethoxy-; AC1L4ODP; HY-N0226; cid_160876; AC1Q701H 337
TCMBANKIN046015 saringosterol Saringosterol; 24-vinyl-cholest-5-ene-3beta,24-diol; LMST01040167; CHEMBL252366 C29H48O2 429 C1([H])([H])C([H])([H])[C@@]2(C([H])([H])[H])C(=C([H])C([H])([H])[C@]3([H])[C@]2([H])C([H])([H])C([H])([H])[C@](C([H])([H])[H])([C@@]([H])([C@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])[C@](O[H])(C([ H])=C([H])[H])C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])C4([H])[H])[C@@]34[H])C([H])([H])[C@@]1([H])O[H]
TCMBANKIN046636 sophoflavescenol 216450-65-6; CHEMBL77651; SCHEMBL14563970; LMPK12112538; MolPort-039-339-033; AK685650; 3,7-Dihydroxy-2-(4-hydroxy-phenyl)-5-methoxy-8-(3-methyl-but-2-enyl)-chromen-4-one; CS-6033; ZINC4199939; BDBM50116711; 3,7-dihydroxy-2-(4-hydroxyphenyl)-5-methoxy-8-(3-methylbut-2-enyl)-4H-chromen-4-one; HY-N2284; D00QCL; SOPHOFLAVESCENOL; AKOS032945037 C21H20O6 368.4 g/mol CC(=CCC1=C2C(=C(C=C1O)OC)C(=O)C(=C(O2)C3=CC=C(C=C3)O)O)C
TCMBANKIN060364 thalictrifoline C21H23NO4 353.41 CC1C2C3=CC(=C(C=C3CCN2CC4=C1C=CC5=C4OCO5)OC)OC
TCMBANKIN061320 cryptopine C21H23NO5 369.41 CN1CCC2=CC(=C(C=C2C(=O)CC3=C(C1)C4=C(C=C3)OCO4)OC)OC
TCMBANKIN061465 papaveraldine xanthaline C20H19NO5 353.37 g/mol COC1=C(C=C(C=C1)C(=O)C2=NC=CC3=CC(=C(C=C32)OC)OC)OC
TCMBANKIN061671 dl-tetrahydropalmatine dl-tetrahydropalmatine;AIDS002241; 84-38-8; 13a-alpha-Berbine, 2,3,9,10-tetramethoxy-; CHEBI:16563; 6H-Dibenzo(a,g)quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, (S)-; (S)-5,8,13,13a-Tetrahydro-2,3,9,10-tetramethoxy-6H-dibenzo(a,g)quinolizine; AIDS-002241; C02890; Hyndarine; (-)-Corydalis; 4880-82-4 (HCL); NSC36363 (HCL); InChI=1/C21H25NO4/c1-23-18-6-5-13-9-17-15-11-20(25-3)19(24-2)10-14(15)7-8-22(17)12-16(13)21(18)26-4/h5-6,10-11,17H,7-9,12H2,1-4H3/t17-/m0/s; 5,8,13,13a-Tetrahydro-2,3,9,10-tetramethoxy-6H-dibenzo(a,g)quinolizine; 5,8,13,13a(S)-Tetrahydro-2,3,9,10-tetramethoxy-6H-dibenzo[a,g]quinolizine; 2-(2,3-Dimethoxy-benzyl)-1-ethyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline; BB_NC-1018; Gindarine; Tetrahydropalmatine (6CI); Berbine, 2,3,9,10-tetramethoxy- (8CI); Tetrahydropalmatine; l-Tetrahydropalmatine; (S)-Tetrahydropalmatine; Caseanine; 6H-Dibenzo(a,g)quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-; Rotundine; (13aS)-2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline; 483-14-7; (13aS)-2,3,9,10-tetramethoxy-5,8,13,13a-tetrahydro-6H-isoquino[3,2-a]isoquinoline; 6H-dibenzo[a,g]quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, (13aS)-; (-)-Tetrahydropalmatine;2,3,9,10-Tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[3,2-a]isoquinoline hydrochloride; 2,3,9,10-Tetramethoxy-5,8,13,13a-tetrahydro-6H-isoquino[3,2-a]isoquinoline hydrochloride; AKOS024399264; MolPort-002-321-247; Berbine,3,9,10-tetramethoxy-, hydrochloride; NSC-132057; NSC-209411; 2,3,9,10-Tetramethoxyberbine hydrochloride; 6024-85-7; CHEMBL1412574; NSC132058; Palmatine, hydrochloride, (.+-.)-; 6H-Dibenzo[a, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, hydrochloride, (R)-; Tetrahydropalmatine hydrochloride; 024T857; C-55689; MCULE-7006385138; Palmatine, hydrochloride, (+)-; A832652; 6H-Dibenzo[a, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, hydrochloride; MLS000029596; Ambotz6024-85-7; 2506-20-9; FT-0698667; 6H-Dibenzo[a, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, hydrochloride, (.+-.)-; WLN: T D6 B666 KN&TT&J GO1 HO1 PO1 QO1 &GH; AC1O7ERI; NSC132057; NSC-132058; MLS002535962; AK310574; 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline hydrochloride; AC-8031; 13a.beta.-Berbine,3,9,10-tetramethoxy-, hydrochloride; Berbine,3,9,10-tetramethoxy-, hydrochloride, (+)-; NSC209411; Berbine,3,9,10-tetramethoxy-, hydrochloride, (.+-.)-; 3,4,10,11-tetramethoxy-7,8,12b,13-tetrahydro-5H-6000000-azatetraphene hydrochloride; SCHEMBL3502167; AC1Q3C4E; D-Tetrahydropalmatine hydrochloride; Tetrahydropalmatine, HCl; SMR000008833;(13aR)-2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline;Hyndarin;tetrahydropalmatine;L-tetrahydropalmatine;STOCK1N-14407 C21H25NO4 355.4 g/mol COC1=C(C2=C(CC3C4=CC(=C(C=C4CCN3C2)OC)OC)C=C1)OC
TCMBANKIN061781 hernandin 69222-20-4 (UNSPECIFIED); AIDS006791; Deoxypodophyllotoxin; AIDS-006791; (5aR,8aR,9R)-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofurano[5,6-f][1,3]benzodioxol-8-one; (-)-Deoxypodophyllotoxin; (-)-Anthricin; Hernandin; Anthricin; DPT; Podophyllotoxin, deoxy-; SILICICOLIN; Desoxypodophyllotoxin; Anthriscin; NCI60_003794; (-)-Desoxypodophyllotoxin; 19186-35-7; 19186-35-7 (5R,5AR,8AR); Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(3,4,5-trimethoxyphenyl)-,(5R,5aR,8aR)-; 5,8,8a,9,-Tetrahydro-5-(3,4,5-trimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one; NSC403148; Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(3,4,5-trimethoxyphenyl)-, (5R,5aR,8aR)-; C10556; 4-Deoxypodophyllotoxin; deoxypodophyllotoxin; (-)-deoxypodophyllotoxin; anthricin isomer; isoanthricin; anthricin C22H22O7 398.4 g/mol COC1=CC(=CC(=C1OC)OC)C2C3C(CC4=CC5=C(C=C24)OCO5)COC3=O
TCMBANKIN061787 (-)-yatein Dihydroanhydropodorhizol; 2(3H)-Furanone,4-(1,3-benzodioxol-5-ylmethyl)dihydro-3-[(3,4,5-trimethoxyphenyl)methyl]-,(3R-trans)-; (3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]-2-tetrahydrofuranone; MolPort-035-706-087; AC1L9DHE; (-)-deoxypodorhizone; (3r,4r)-4-(1,3-benzodioxol-5-ylmethyl) dihydro-3-[(3,4,5-trimethoxyphenyl)methyl]-2(3h)-furanone; 2(3H)-Furanone,4-(1,3-benzodioxol-5-ylmethyl)dihydro-3-((3,4,5-trimethoxyphenyl)methyl)-,trans-(-)-; GMLDZDDTZKXJLU-JKSUJKDBSA-N; AKOS032948829; (3R,4R)-4-[(2H-1,3-benzodioxol-5-yl)methyl]-3-[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-one; ZINC1575142; (-)-yatein; Deoxypodorhizone; CHEMBL471067; (3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]tetrahydrofuran-2-one; Yatein; DTXSID50193471; 40456-50-6; RD4-6277; BG01688458; AIDS-218539; AIDS218539; SCHEMBL1037807; 2(3H)-Furanone,4-(1,3-benzodioxol-5-ylmethyl)dihydro-3-[(3,4,5-trimethoxyphenyl)methyl]-,(3R,4R)-; D01FBL; (3R,4R)-4-(Benzo[d][1,3]dioxol-5-ylmethyl)-3-(3,4,5-trimethoxybenzyl)dihydrofuran-2(3H)-one; W1872; (3R,4R)-4-(1,3-Benzodioxol-5-ylmethyl)-3-(3,4,5-trimethoxybenzyl)dihydrofuran-2(3H)-one; (-)-trans-3-(3,4-Methylenedioxybenzyl)-2-(3,4,5-trimethoxybenzyl)butyrolactone; CHEBI:4553; C22H24O7; (3R,4R)-4-(2H-1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-one; C10557; (3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-one; dihydroanhydropodorhizol; BDBM50241524; Deoxypodorhizon; (3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-3-(3,4,5-trimethoxybenzyl)tetrahydrofuran-2-one C22H24O7 400.42 g/mol COC1=CC(=CC(=C1OC)OC)CC2C(COC2=O)CC3=CC4=C(C=C3)OCO4

   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI000054 Nervous System Diseases; Mental Disorders Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI000066 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction disease
TCMBANKDI000088 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process group
TCMBANKDI000121 Pathological Conditions, Signs and Symptoms; Nervous System Diseases Abnormality of the nervous system; Abnormality of the musculature Finding phenotype
TCMBANKDI000166 - - Neoplastic Process disease
TCMBANKDI003353 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process phenotype
TCMBANKDI003411 - - Disease or Syndrome disease
TCMBANKDI004145 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction group
TCMBANKDI009489 - - Sign or Symptom phenotype
TCMBANKDI010896 Nervous System Diseases Abnormality of the nervous system Disease or Syndrome group
TCMBANKDI011234 Pathological Conditions, Signs and Symptoms; Hemic and Lymphatic Diseases - Disease or Syndrome disease
TCMBANKDI011758 - - Laboratory Procedure phenotype
TCMBANKDI012157 Nervous System Diseases Abnormality of the nervous system Disease or Syndrome group
TCMBANKDI014689 - Abnormality of the nervous system Finding phenotype
TCMBANKDI014716 Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI015030 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI015485 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction disease
TCMBANKDI016612 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction phenotype
TCMBANKDI017024 Neoplasms; Respiratory Tract Diseases - Neoplastic Process disease
TCMBANKDI017673 - - Clinical Attribute phenotype
TCMBANKDI019267 Pathological Conditions, Signs and Symptoms; Nervous System Diseases Abnormality of the nervous system Sign or Symptom phenotype
TCMBANKDI020119 Mental Disorders Abnormality of the nervous system Finding phenotype
TCMBANKDI021622 Mental Disorders - Mental or Behavioral Dysfunction disease
TCMBANKDI024535 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI029054 Mental Disorders - Mental or Behavioral Dysfunction group
TCMBANKDI030678 Digestive System Diseases; Neoplasms - Neoplastic Process group
TCMBANKDI031570 - Abnormality of the nervous system Mental or Behavioral Dysfunction disease
TCMBANKDI032417 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction disease